Hypolipidemic Effects of Modified Edamame Tempeh Flour on Lipid Profile Levels in Dyslipidemia Rats

Efek Hipolipidemia Tepung Tempe Edamame Modifikasi terhadap Profil Lipid Tikus Model Dislipidemia

Dika Nurkistin*1, Didik Gunawan Tamtomo2, Budiyanti Wiboworini3

1Master Program of Nutrition Sciences, School of Postgraduate, Universitas Sebelas Maret, Surakarta, Indonesia
2Department of Public Health, School of Postgraduate, Universitas Sebelas Maret, Surakarta, Indonesia
3Department of Nutrition, School of Postgraduate, Universitas Sebelas Maret, Surakarta, Indonesia

ABSTRACT

Background: Dyslipidemia is a lipid metabolism disorder that causes an increase or decrease in plasma lipid concentrations. Comprehensive management is an attempt to prevent and reduce dyslipidemia, one of which is nutritional therapy. Edamame contains nutrients such as protein, fat, fiber, and isoflavones that have the potential to improve lipid profiles. Edamame tempeh production is one way to improve product quality that is improving nutritional quality, digestibility, and bioavailability. Edamame tempeh modification is conducted by adding yeast Saccharomyces cerevisiae. This yeast plays a role in increasing the isoflavone levels and the product containing β-glucan.

Objectives: This research aims to analyze the effects of edamame tempeh flour (ET) and modified edamame tempeh flour (MET) on lipid profile levels in dyslipidemic rats.

Methods: This research was a true experimental with a randomized controlled group pretest-posttest design. Thirty-six Sprague Dawley male white rats that met the inclusion criteria were randomized and divided into six treatment groups consisting of negative control, positive control, the dose of ET flour was 2.7 g/200gBW and 5.4 g/200gBW, the dose of MET flour was 2.7 g/200gBW and 5.4 g/200gBW. The intervention was carried out once per day in the morning for 28 days. The parameters observed included total cholesterol, LDL-C, and HDL-C levels measured by the CHOP-PAP method and triglyceride levels using the GPO-PAP method with a spectrophotometer measuring instrument. Examination of lipid profile levels was carried out three times. All statistical tests used a 95% significance level.

Results: There was a significant difference in the decrease in total cholesterol, LDL-C, and triglyceride levels as well as an increase in HDL-C levels compared to before the intervention (p<0.05).

Conclusions: The administration of ET flour and MET flour could significantly reduce total cholesterol, LDL-C, triglyceride, and increased HDL-C, but the administration of MET flour, especially at a dose of 5.4 g/200gBW, showed a more effective improvement in lipid profile and approached the positive control group compared to ET flour.

Latar Belakang: Dislipidemia merupakan kelainan metabolisme lipid yang menyebabkan peningkatan atau penurunan konsentrasi lipid dalam plasma. Pengendalian secara komprehensif sebagai upaya dalam mencegah dan menurunkan dislipidemia salah satunya dengan terapi gizi. Edamame memiliki kandungan gizi seperti protein, lemak, serat, dan isoflavon yang berpotensi dalam perbaikan profil lipid. Produksi tempe edamame merupakan salah satu cara meningkatkan mutu produk yaitu meningkatkan kualitas gizi, daya cerna, dan bioavailabilitas. Tempe edamame modifikasi dilakukan dengan menambahkan khamir Saccharomyces cerevisiae. Khamir ini ikut berperan dalam peningkatan kadar isoflavon dan produk yang hasilkan mengandung β-glucan.

Tujuan: Penelitian ini merupakan true experimental dengan rancangan randomized controlled group pretest-posttest. Tiga puluh enam tikus jantan putih galur Sprague Dawley yang memenuhi kriteria inklusi diacak dan dibagi menjadi 6 kelompok perlaku. Tujuan penelitian ini adalah untuk mengetahui efek hipolipidemia tepung tempe edamame (ET) dan tepung tempe edamame modifikasi (MET) terhadap profil lipid tikus model dislipidemia.

Metode: Penelitian ini menggunakan metode true experimental dengan rancangan randomized controlled group pretest-posttest. Tiga puluh enam tikus jantan putih galur Sprague Dawley yang memenuhi kriteria inklusi diacak dan dibagi menjadi 6 kelompok perlaku terdiri dari kontrol negatif, kontrol positif, pemberian tepung ET dosis 2,7 g/200gBB dan 5,4 g/200gBB, dan MET dosis 2,7 g/200gBB dan 5,4 g/200gBB. Pengukuran profil lipid dilakukan tiga kali sebelum dan setelah intervensi.
INTRODUCTION
Dyslipidemia is an abnormal lipid metabolism that causes an increase or decrease in plasma lipid concentrations characterized by increased levels of total cholesterol, LDL-C, triglycerides, and decreased levels of HDL-C. Dyslipidemia contributes to endothelial dysfunction which is a major factor in the pathogenesis of hypertension, thrombosis, and atherosclerosis. Atherosclerosis causes blood flow to the heart muscle to be blocked and results in cardiovascular disease. One of the management of dyslipidemia therapy is through food regulation. Nutritional therapy is an important supporting factor in the management of dyslipidemia. Nutrition therapy has shown effectiveness in efforts to reduce dyslipidemia including proper energy intake to maintain a normal weight, limiting saturated fat intake, limiting simple carbohydrates intake, consuming high fiber foods, limiting alcohol consumption, and implementing the consumption of functional food sources in the daily diet. One of the functional foods that are closely related to antidyshlipidemia is tempeh. Tempeh has high nutritional values such as a source of protein, vitamin B12, and bioactive compounds. The nutritional value of tempeh is recognized to support the improvement of dyslipidemia. The main protein content in soybeans is globulin 7S (β-conglycinin) and globulin 11S (glycinin) which play a role in increasing bile salt secretion and inhibiting cholesterol absorption.

In general, tempeh is made from yellow soybeans or mature soybeans, but edamame can also be an alternative material for tempeh production. Edamame or vegetable soybeans are rich in protein, vitamins, minerals, dietary fiber, calcium, iron, and bioactive compounds such as omega-3 fatty acids, sterols, isoflavones, and saponins, and high in essential amino acids. Edamame tempeh is a processed food from soybean derivatives as the attempts to increase the nutritional content and digestibility of the product. The presence of enzymatic activity from the fungus Rhizopus oligosporus can reduce antinutrient compounds in beans and convert them from macromolecular substrates into simple forms such as amino acids, fatty acids, isoflavone aglycones, and other bioactive compounds so that they are more easily utilized by the body.

In addition, during the soybean fermentation process, other microorganisms can grow, such as the yeast Saccharomyces cerevisiae. Yeast S. cerevisiae is involved in the breakdown of glycosides into aglycones increasing the availability of isoflavone aglycones. S. cerevisiae is one of the microorganisms that produce β-glucan. β-glucan is effective in preventing an increase in blood cholesterol levels. Therefore, tempeh produced with the addition of S. cerevisiae has the advantage of increasing the quality of tempeh with high β-glucan content.

Previous research has studied the health benefits of tempeh, while in this research the main material used is edamame. In addition, edamame tempeh in this research was modified by adding yeast S. cerevisiae. This modification process produces edamame tempeh with higher nutritional value. Based on the background, this research aimed to analyze the effect of edamame tempeh flour (ET) and modified edamame tempeh flour (MET) on lipid profile levels of dyslipidemic rats.

METHODS
Design, Time, Place of Research
This research was a true experimental with a randomized controlled group pretest-posttest design. The research was carried out in September-November 2021 at the Laboratory of the Center for Food and Nutrition Studies, Inter-university Center, Universitas Gadjah Mada, Yogyakarta. This research was declared ethically feasibly by the Research Ethics Committee of the Faculty of Medical Sciences, Universitas Sebelas Maret No. 49/UN27.06.6.1/KEP/EC/2021 on 7 June 2021.

Equipment and Materials
The equipment consisted of analytical digital scales, containers/basins, stoves, frying pans/pans, stirrers/spatulas, strainers, polyethylene (PE) plastic, freeze dryer, miller machine, measuring cups, mortar, and pestle, mixing spoon, experimental animals equipped with eating and drinking utensils, experimental animal scales, gloves, gastric probe, injection syringe, serum separator tube (SST), microhematocrit tube, micropipette, vortex mixer genie 2, centrifuge (Heraeus MegaFuge 1.0), spectrophotometer (SP 300; Optima, Japan).

The materials used in this research included edamame from Pasirhalang, Sukaraja District, Sukabumi Regency, West Java Province, tempeh yeast Rhizopus oligosporus RAPRIMA brand, yeast Saccharomyces cerevisiae commercial Fermipan brand, male white rats.
Sprague Dawley, aquades, standard feed comfeed, simvastatin drug, pork oil and duck egg yolk.

Research Material Preparation
The stages of making edamame tempeh and modifications consist of sorting, washing, and boiling for ± 30 minutes, peeling the outer skin and epidermis, dividing the edamame seeds into two parts, soaking for ± 18 hours, boiling again for ± 15 minutes, drying and adding 2 g/kg of tempeh yeast and adding 3% S. cerevisiae yeast, stirring, packaging, and fermentation at 28°C for 36 hours.

The process of making edamame tempeh and modification flour was conducted by slicing tempeh that has been aged for 36 hours, slicing with a thickness of 0.1 mm, steaming for ± 5 minutes, freezing in the freezer, drying using a freeze-drying method for 24 hours, milling with a miller machine for ± 30 seconds.

Research Sample
The sample used was a white rat (Rattus norvegicus) Sprague Dawley strain with inclusion criteria including male rats, body weight ranging from 150-200 g, 8 weeks old, and normal behavior. Samples that were not included in the research if they had the exclusion criteria, the rats experienced behavioral changes and diarrhea which was indicated by watery stools, and the dropout criteria were that the rats died during the research.

Table 1. Experimental design

| Treatment Group | Intervention                      |
|-----------------|-----------------------------------|
| K-              | Dyslipidemic rats                  |
| K+              | Dyslipidemic rats + simvastatin 0.18 mg/200gBW |
| KP1             | Dyslipidemic rats + ET flour dose 2.7 g/200gBW |
| KP2             | Dyslipidemic rats + ET flour dose 5.4 g/200gBW |
| KP3             | Dyslipidemic rats + MET flour dose 2.7 g/200gBW |
| KP4             | Dyslipidemic rats + MET flour dose 5.4 g/200gBW |

The treatment group consisted of negative control (K-), namely dyslipidemic rats that were not given the intervention, a positive control (K+) that was given the simvastatin drug, KP1 was the group that was given the intervention of ET flour at a dose of 2.7 g/200gBW, KP2 was the group that was given the intervention of ET at a dose of 5.4/200gBW, KP3 is the group that was given the intervention of MET flour at a dose of 2.7 g/200gBW, and KP4 is the group that was given the MET flour intervention at a dose of 5.4/200gBW.

Table 2. Research time

| Time            | Implementation                           |
|-----------------|-----------------------------------------|
| Day 1-Day 7     | Experimental rats adaptation period      |
| Day 8-Day 21    | Induction HFD for all treatment groups   |
| Day 22-Day 50   | Intervention                             |

Dosage Determination
The dose of simvastatin for dyslipidemic adults is 10 mg/day converted according to Laurence and Bacharach’s table for Rattus norvegicus so that the dose of simvastatin is given to rats is 0.18 mg/200gBW. The determination of dose was determined based on the consumption of tempeh per day according to the vegetable protein exchange unit equivalent to 150 g of tempeh. The amount was converted so that the dose of ET flour was 2.7 g/200gBW (normal dose) and 5.4 g/200gBW (high dose) and MET flour 2.7 g/200gBW (normal dose) and 5.4 g/200gBW (high dose). The intervention was given once per day in the morning for 28 days.

Data Collection
Parameters observed in this research included levels of lipid profile (total cholesterol, LDL-C, HDL-C, and triglycerides). The sample used was rat’ blood serum taken through the vein retro-orbital. Examination of total cholesterol, LDL-C, and HDL-C levels was obtained from the results of the enzymatic photometric
**Cholesterol Oxidase-Peroxidase Aminoantipyrine Phenol (CHOP-PAP) test** and triglyceride levels using the **Glycerol-3-Phosphate-Peroxidase Aminoantipyrine Phenol (GPO-PAP)** method. Then, it was analyzed using a measure the spectrophotometer. Lipid profile levels in rats were measured three times after adaptation (before HFD induction), before intervention (after HFD induction), and after intervention.

**Data Analysis**

The data obtained were tested for normality using the *Shapiro-Wilk* test. Next, the data that were normally distributed were followed by a homogeneity test using *Levene’s Test*. Data that were normally distributed and homogeneous can be continued with the *One-Way ANOVA* test. A *One-Way ANOVA* test was used to analyze the differences between each treatment group. Next, it was followed by the *Post Hoc Tukey High Significant Difference* (*HSD*) test, the data were normally distributed but not homogeneous. The next test was the *Games-Howell* test. The data were not normally distributed but homogeneous so using the *Kruskal Wallis* non-parametric statistical test followed by the *Mann-Whitney* test. All statistical tests used a 95% significance level.

**RESULTS AND DISCUSSION**

**Total Cholesterol**

Based on Table 2, the average total cholesterol levels in all treatment groups decreased after being given the intervention. The results of statistical tests indicated significant differences in the four groups compared to before the intervention (*p*<0.05). The highest decrease occurred in the positive control group who were given simvastatin as much as 52.55% and the lowest decrease in cholesterol was in KP1 as much as 30.28%. The intervention group that experienced a decrease in cholesterol levels was closed to the positive control group that is the KP4 group (50.17%).

**Table 3. Average changes in total cholesterol levels after intervention**

| Group | Average Total Cholesterol Levels (mg/dl) | Rate of Change | %
|-------|------------------------------------------|----------------|------|
|       | D1 | D28 | Δ Total Cholesterol (mg/dl) |       |
| K-    | 193.50 ± 3.02 | 195.08 ± 2.67 | 1.58 ± 0.35 | 0.82 |
| K+    | 193.62 ± 2.87 | 91.88 ± 1.38 | -101.74 ± 1.49 | 52.55 |
| KP1   | 190.19 ± 5.17 | 132.60 ± 1.59 | -57.59 ± 3.58 | 30.28 |
| KP2   | 188.30 ± 4.68 | 108.49 ± 3.43 | -79.81 ± 1.25 | 42.38 |
| KP3   | 189.24 ± 5.78 | 101.23 ± 1.71 | -88.01 ± 4.07 | 46.51 |
| KP4   | 190.78 ± 2.05 | 95.07 ± 1.83 | -95.71 ± 0.22 | 50.17 |

The number is mean ± deviation standard

KP1 = ET flour dose 2.7 g/200gBW; KP2 = ET flour dose 5.4 g/200gBW; KP3 = MET flour dose 2.7 g/200gBW; KP4 = flour dose MET 5.4 g/200gBW

Δ = The difference between D1 and D28

D1 = Before intervention (post HFD induction); D28 = after intervention

(1) *One-Way ANOVA*

(2) *Kruskal Wallis*

(*) There is a significant difference (*p*<0.05)

Table 3 is a *Mann-Whitney* test to determine the difference in the difference in total cholesterol levels in each treatment group before and after being given the intervention. The results of the analysis showed the difference in total cholesterol levels was significantly different between the treatment groups after being given the intervention for 28 days (*p*<0.05), but in KP2 and KP3 there was no significant difference (*p*>0.05). This showed that the administration of ET flour at a dose of 5.4 g/200gBW and MET flour at a dose of 2.7 g/200gBW has almost the same effect on lowering total cholesterol levels.

**Table 4. Post Hoc analysis of differences in total cholesterol levels before and after intervention**

| Parameter | KP1 | KP2 | KP3 |
|-----------|-----|-----|-----|
| Δ Total Cholesterol | 0.004* | 0.004* | 0.004* |
| KP1       |      | 0.004* | 0.004* |
| KP2       | 0.004* |      | 0.078 |
| KP3       | 0.004* | 0.004* |      |
| KP4       | 0.004* | 0.006* | 0.016* |

(*) There is a significant difference (*p*<0.05)

Soybeans and their processed products were closely related to foods high in protein, essential fatty acids, as well as vitamins, and minerals. This had a direct effect on the body’s metabolic processes. Based on the results of statistical analysis, total cholesterol levels decreased significantly in the intervention group with ET flour and MET flour. The hypocholesterolemic effect on MET flour occurred because soy protein was a fundamental component in soybeans. After all, it had a beneficial effect on lipid metabolism. The main protein content in soybeans are 7S globulin (β-conglycinin) and 11S globulin (glycinin). Lammi et al. (2015) found two hypolipidemic peptides namely YVVNPDNDEN and YVVNPDNNEk derived from soy protein globulin β-conglycinin which could modulate cholesterol. Peptide IAVPGEVA was derived from soy glycinin, this peptide...
could work with bile acids to lower plasma cholesterol levels in the liver increasing plasma cholesterol levels\(^3\). In addition, the low content of methionine in soybeans is associated with hypocholesterolemia which has positive homocysteine levels and can induce hypercholesterolemia by increasing cholesterol synthesis in the liver, so that in an increase in plasma cholesterol levels\(^2\). The recommendation for soy protein intake in improving lipid profiles was 25 g/day\(^3\).

In addition, the fiber content in soybeans played a role in reducing cholesterol levels caused by the ability of fiber to modulate intestinal microbiota to reduce cholesterol synthesis due to the formation of propionate which inhibits the action of the HMG-CoA reductase enzyme in decreasing the diffusion of bile salts\(^5\). The recommended daily fiber intake for adults was 25-38 g\(^2\). Research by Huang et al., (2018) proved that hyperglycemic rats induced by HFD experienced a decrease in cholesterol levels after being given tempeh supplementation which was inoculated with \textit{Lactobacillus plantarum}. Based on the results of research related to cholesterol levels, it was found that the MET flour group was more effective than ET flour due to the compounds contained in the two products. Edamame tempeh added due to the compounds contained in the two products. The number is mean ± deviation standard.

However, soy isoflavones had an anticholesterol effect because they were able to bind to estrogen receptors on body cells, thereby affecting the function of estrogen in binding DNA sequences and inducing DNA transcription. Through this mechanism, isoflavones became ligands for lipid regulating proteins such as PPARs (\textit{ Peroxisome Proliferator-Activated Receptors}), liver X receptors, and farnesoid X receptors that carried out a leading role in lipid metabolism. Therefore, this mechanism could reduce lipid synthesis in the liver, bile salt synthesis, and cholesterol reabsorption\(^6\). Isoflavones in tempeh were isoflavone aglycones that were more easily absorbed by the body. During the fermentation process, microorganisms helped activate isoflavones from glycone forms (daidzin and genistin) to aglycones (daidzein and genistein)\(^1,7\).

### Low-Density Lipoprotein Cholesterol (LDL-C)

Based on table 4, it can be seen that the average change in LDL-C levels in the rats group after the intervention decreased. Statistical analysis showed a significant difference between LDL-C levels before and after the intervention (p<0.05). The treatment group that experienced the highest decrease in LDL-C levels was the positive control group (simvastatin), which was 60.51%. The effect of giving the intervention of MET flour at a dose of 5.4 g/200gBW (KP4) could reduce LDL-C levels (57.27%) close to the positive control group and the lowest reduction in LDL-C levels is in KP1 of 33.82%.

#### Table 5. Average changes in LDL-C levels after intervention

| Group  | Average LDL-C Levels (mg/dl) | Rate of Change | % |
|--------|------------------------------|----------------|---|
|        | D1                           | D28            | Δ LDL-C (mg/dl) | %   |
| K-     | 83.16 ± 2.41                 | 84.39 ± 2.22   | 1.23 ± 0.19     | 1.48 |
| K+     | 83.05 ± 1.27                 | 32.80 ± 1.56   | -50.25 ± 0.29   | 60.51 |
| KP1    | 79.54 ± 2.59                 | 52.64 ± 2.49   | -26.90 ± 0.10   | 33.82 |
| KP2    | 81.92 ± 5.35                 | 41.00 ± 1.71   | -40.92 ± 3.64   | 49.95 |
| KP3    | 82.82 ± 3.07                 | 38.62 ± 2.05   | -44.20 ± 1.02   | 53.37 |
| KP4    | 80.79 ± 1.79                 | 34.52 ± 1.48   | -46.27 ± 0.31   | 57.27 |

\( p \) 0.259 0.001* 0.001*

\( \Delta \) = The difference between D1 and D28

\( \Delta \) LDL-C before and after intervention (p<0.05)

The results of the follow-up test using the Post Hoc Tukey HSD test revealed that there was a significant difference in LDL-C levels between the treatment groups (p<0.05) except in the positive control group with KP2 and KP4, KP2 with KP3 and KP4 were not significantly different (p>0.05). This shows that ET flour at a dose of 5.4 g/200gBW, MET flour at a dose of 2.7 g/200gBW, and 5.4 g/200gBW had almost the same effect on lowering LDL-C levels (Table 5).

#### Table 6. Post Hoc analysis of differences in LDL-C levels before and after intervention

| Parameter  | K- | K+ | KP1 | KP2 | KP3 |
|------------|----|----|-----|-----|-----|
| \( \Delta \) LDL-C | 0.001* | 0.001* | 0.022* | 0.001* | 0.887 |
| KP1        | 0.001* | 0.125 | 0.022* | 0.887 | 0.550 |
| KP2        | 0.001* | 0.041* | 0.001* | 0.887 | 0.550 |
| KP3        | 0.001* | 0.188 | 0.001* | 0.887 | 0.550 |

\( (*) \) There is a significant difference (p<0.05)
LDL-C was the main lipoprotein that had atherogenic properties so it becomes a target for improving the lipid profile. Edamame had nutritional components and bioactive compounds in improving LDL-C levels including protein, unsaturated fatty acids, fiber, isoflavones, and vitamins. Amino acids, fiber, and high isoflavones content in soybeans had the potential as cardioprotective in lowering LDL-C levels.

The results of the research related to LDL-C levels indicated that each treatment group that was given the intervention of ET flour and MET flour had a significant decrease. Based on the results of the analysis, it was recognized that the reduction in LDL-C levels was more effective in the group with MET flour compared to ET flour. This might have happened because the main protein components in soybeans were globulin 7S (β-conglycinin) and globulin 11S (glycinin). This peptide had a physiological effect in reducing LDL-C levels by degrading LDL-C in the liver, resulting in a decrease in serum LDL-C levels. In addition, the peptides obtained from soybean glycinin are IAVPGEVA, IAVPTGVA, and LPYP. These three peptides could increase LDL-C receptor activity and work in vitro as inhibitors of HMG-CoA Reductase activity to regulate cholesterol biosynthesis. This would decrease the synthesis of cholesterol in the intracellular which led to the activation of SREBP-2 and increased the absorption of LDL-C by Hep2 cells. Another peptide derived from β-glucan, namely FVVNATSN could increase the transcription of LDL-C receptors in hepatocytes and the small subunit of albumin 25 protein (lunasin) plays a role in improving LDL-C levels through the mechanism of decreasing HMG-CoA reductase expression and increasing LDL-C receptor expression.

The fiber content and unsaturated fatty acids in soy such as omega-3 and omega-9 fatty acids have been shown to reduce LDL-C levels in the blood. The fat contained in soybeans was mostly unsaturated in the form of arachidonic fatty acids, linoleic fatty acid, and oleic fatty acid, and contained phospholipids such as lipoprotein, sepalin, and lecithin. This is in line with the research of Huang et al. (2018) that reported supplementation of tempeh co-inoculated with Lactobacillus Plantarum in induced hyperglycemic rats HFD significantly lowers LDL-C levels.

The decrease in LDL-C levels was more common in the group with MET flour administration also due to the presence of β-glucan compounds which played a role in increasing the number of LDL-C receptors in the liver, thereby eliminating LDL-C particles in plasma. This was evidenced by the research of Grundy et al. (2018) that stated there was a decrease in LDL-C levels in hypercholesterolemic rats fed a diet containing β-glucan.

**High-Density Lipoprotein Cholesterol (HDL-C)**

Table 6 shows that HDL-C levels in the rats treatment group increased with the administration of ET flour and MET flour interventions for 28 days and statistically the average HDL-C levels before and after the intervention were significantly different (p<0.05). The KP4 group was known to have the best HDL levels among the other intervention groups with a value of 71.55 mg/dl or an increase of 204.21% compared to HDL-C levels before the intervention. KP4 is the intervention group that is closest to the positive control HDL-C levels, which was 70.71 mg/dl (209.45%).

| Group       | Average HDL-C Levels (mg/dl) | Rate of Change |
|-------------|-------------------------------|---------------|
|             | D1               | D28             | Δ HDL-C (mg/dl) | %             |
| K-          | 22.63 ± 1.86     | 21.89 ± 1.93    | -0.74 ± 0.07   | 3.27          |
| K+          | 22.85 ± 1.96     | 70.71 ± 1.56    | 47.86 ± 0.40   | 209.45        |
| KP1         | 23.63 ± 1.45     | 56.34 ± 2.16    | 32.71 ± 0.71   | 138.43        |
| KP2         | 23.30 ± 1.96     | 63.87 ± 1.81    | 40.57 ± 0.15   | 174.12        |
| KP3         | 23.30 ± 1.86     | 67.36 ± 1.57    | 44.06 ± 0.29   | 189.10        |
| KP4         | 23.52 ± 1.55     | 71.55 ± 1.56    | 48.03 ± 0.01   | 204.21        |
| P           | 0.918            | 0.001*          | 0.001*         |               |

The number is mean ± deviation standard
KP1 = ET flour dose 2.7 g/200gBW; KP2 = ET flour dose 5.4 g/200gBW; KP3 = MET flour dose 2.7 g/200gBW; KP4 = flour dose MET 5.4 g/200gBW
Δ = The difference between D1 and D28
D1 = Before intervention (post HFD induction); D28 = after intervention
(*) There is a significant difference (p<0.05)

Post-Hoc Tukey HSD test in Table 7 showed that there was a significant difference between the treatment groups (p<0.05), but the positive control was not significantly different from KP3 and KP4, KP2 and KP3, KP3 and KP4 (p>0.05). Based on the results of the analysis, showed that MET flour was able to increase HDL-C levels close to positive control compared to ET flour. The group given ET flour at a dose of 5.4 g/200gBW had the effect of increasing HDL-C levels which was almost the same as the MET flour at a dose of 2.7 g/200gBW, while the group given TEM flour at a dose of 2.7 g/200gBW was able to increase HDL-C levels in rats not much different from the dose of 5.4 g/200gBW of TEM flour.
Table 8. Post Hoc analysis of differences in HDL-C levels before and after intervention

| Parameter | K- | K+ | KP1 | KP2 | KP3 |
|-----------|----|----|-----|-----|-----|
| Δ HDL-C   | 0.001* | 0.001* | 0.001* | 0.001* | 0.001* |

(*) There is a significant difference (p<0.05)

HDL-C was considered good cholesterol because it acted as a cleanser of excess cholesterol in the arteries by transporting LDL back to the liver and excreted by the body. Table 6 shows that the HDL-C of rats with the effect of administration of the intervention of ET flour and MET flour a significant increase. This research was in line with the research of Astawan et al. (2015) which stated that rats fed tempeh rations experienced an increase in HDL-C levels compared to boiled soybean or casein rations. This was influenced by the presence of oleic, linoleic, and linolenic acids in tempeh which had the potential to increase HDL-C levels.

In addition, the results obtained showed that MET flour increased higher HDL-C levels in rats compared to ET flour. This was because the high content of isoflavone aglycones in MET flour has the potential to increase HDL-C levels. The higher isoflavone content in the product had a greater effect on increasing HDL-C levels. Soy isoflavone aglycones consisting of genistein, daidzein, and glycitein exhibit estrogenic effects which acted as a cardioprotective effect to maintain and increase HDL-C levels.

Table 9. Average changes in triglyceride levels after intervention

| Group  | Average Triglyceride Levels (mg/dl) | Rate of Change |
|--------|------------------------------------|----------------|
|        | D1 | D28 | Δ Triglyceride (mg/dL) | %      |
| K-     | 122.54 ± 4.47 | 124.77 ± 3.17 | 2.23 ± 0.30 | 1.82  |
| K+     | 127.66 ± 7.10 | 81.50 ± 2.77  | -46.16 ± 4.33 | 36.16 |
| KP1    | 117.84 ± 5.89 | 104.11 ± 2.12 | -13.73 ± 3.77 | 11.65 |
| KP2    | 126.14 ± 2.03 | 94.52 ± 1.79  | -31.62 ± 0.24 | 25.07 |
| KP3    | 125.03 ± 4.38 | 93.04 ± 2.19  | -31.99 ± 2.19 | 25.59 |
| KP4    | 123.51 ± 2.43 | 84.02 ± 2.31  | -39.49 ± 0.12 | 31.97 |

The number of mean ± deviation standard

KP1 = ET flour dose 2.7 g/200gBW; KP2 = ET flour dose 5.4 g/200gBW; KP3 = MET flour dose 2.7 g/200gBW; KP4 = flour dose MET 5.4 g/200gBW

Δ = The difference between D1 and D28
D1 = Before intervention (post HFD induction); D28 = after intervention

(*) Kruskal Wallis test

(+) One-Way ANOVA test

(*) There is a significant difference (p<0.05)

Based on the Post Hoc Tukey HSD test, it was found that the treatment groups differed significantly (p<0.05) except that the positive control group did not differ significantly with KP4, KP2 with KP3, and KP4, and KP3 with KP4 (p>0.05). This research showed that the difference in decreasing triglyceride levels with MET flour for 28 days had a greater reduction effect than ET flour. The results of the analysis of the difference in triglyceride levels can be seen in Table 9.

Table 10. Post Hoc analysis of differences in triglyceride levels before and after intervention

| Parameter | K- | K+ | KP1 | KP2 | KP3 |
|-----------|----|----|-----|-----|-----|
| Δ Triglyceride | 0.001* | 0.001* | 0.001* | 0.001* | 0.001* |

Edamame contained about 60% unsaturated fatty acids. High levels of HDL-C in the blood could reduce the occurrence of deposition and plaque formation in the circulatory system. Based on the results of HDL-C analysis obtained, tempeh could be used as a functional food to help reduce the risk of cardiovascular disease through various mechanisms such as removing cholesterol from macrophages, improving endothelial function, and having anti-inflammatory properties.

Triglycerides

The results of the analysis showed that the intervention of giving ET flour and MET flour for 28 days was able to reduce triglyceride levels in all treatment groups. This was evidenced by statistical tests showing a significant difference compared to before the intervention (p<0.05). The treatment group after being given the intervention had the highest triglyceride levels in the KP1 group (104.11 mg/dl) and the lowest was a positive control (81.50 mg/dl) followed by KP4 (84.02 mg/dl).
The results of the research related to triglyceride parameters showed that the intervention treatment group with ET flour and MET flour decreased significantly. This is related to soy protein including β-conglycinin which had been shown to help in lipid metabolism and inhibit lipid synthesis in the liver and cause a decrease in serum triglycerides in rats. Triglyceride levels in the intervention group with MET flour had a better lowering effect than ET flour with the same dose.

Besides, MET flour had a higher content of isoflavone aglycones so there was a greater decrease than the intervention group of ET flour. Isoflavones found in soybeans significantly reduce triglyceride levels. Soy isoflavones were able to modulate lipoproteins resulting in the transformation of several important enzymes regulating lipid metabolisms such as lipoprotein lipase (LPL), and hepatic lipase (HL), or hepatic triglyceride lipase (HTGL), and 7 alpha-hydroxylase. According to the results of a meta-analysis by Nachvak et al. (2019) revealed that the concentration of triglycerides decreased significantly when individuals consumed soy protein containing soy isoflavones.

**CONCLUSIONS**

The administration of ET flour and MET flour gave significant results in reducing total cholesterol, LDL, and triglyceride levels as well as increasing HDL-C levels. Based on the results of the analysis, it was found that MET flour showed better effectiveness as a hypolipidemic functional food compared to ET flour, especially when given MET flour at a dose of 5.4 g/200gBW. This was indicated by the difference in the decrease in total cholesterol, LDL-C, and triglyceride levels as well as an increase in HDL-C levels approaching the positive control group.

**ACKNOWLEDGMENTS**

Authors would like to thank Mr. Yuli Yanto as the field supervisor at the Laboratory of the Center for Food and Nutrition Studies, Universitas Gadjah Mada for assisting in carrying out the research.

**CONFLICT OF INTEREST**

All authors have no conflict of interest in this article.

**REFERENCES**

1. Moor, V. J. A., Amougui, S. N., Ombotto, S., Ntone, F., Wouamba, D. E. & Nonga, B. N. Dyslipidemia in Patients with a Cardiovascular Risk and Disease at the University Teaching Hospital of Yaoundé, Cameroon. Int. J. Vasc. Med. 2017, 1–5 (2017).

2. Ayode, O. G., Umoh, I. & Amadi, C. Dyslipidemia and Associated Risk Factors among Nigerians with Hypertension. Dubai Med. J. 3, 155–161 (2020).

3. Laila, U. & Hermawan, R. Kejadian Hiperkolesterolemia pada Pelaut PT. Samudera

4. Fitriyana, N. I. Potency of functional food from edamame as Hipcholesterolemic Food. J. Rekakangan 11, 10–19 (2017).

5. Gulati, S., Misra, A. & Pandey, R. M. Effects of 3 g of soluble fiber from oats on lipid levels of Asian Indians - a randomized controlled, parallel arm study. Lipids Health Dis. 16, 1–8 (2017).

6. Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y. J., Lim, J. H., Kim, H. J., Choi, S., Moon, M. K., Na, J. O., Park, K., Oh, M. S., Han, S. Y., Noh, J., Yi, K. H., Lee, S., Hong, S. & Jeong, I. 2018 Guidelines for the management of dyslipidemia Cardiovascular disease in Koreans. Korean J. Intern. Med. 34, 723–771 (2019).

7. Priastiti, D. A. & Puruhita, N. Perbedaan Kadar Kolesterol LDL Penderita Dislipidemia pada Pemberian Tempe Kedelai Hitam dan Tempe Kedelai Kuning. J. Nutr. Coll. 2, 262–276 (2013).

8. Ahnan-Winarno, A. D., Cordeiro. L., Winarno, F. G., Gibbons, J. & Xiao, H. Tempeh: A semicentennial review on its health benefits, fermentation, safety, processing, sustainability, and affordability. Compr. Rev. Food Sci. Food Saf. 20, 1717–1767 (2021).

9. Fitriani, D. Y. & Marthandaru, D. Pengaruh susu kedelai dan jahe terhadap kadar kolesterol total pada wanita hiperkolesterolemia. J. Gizi Indones. (The Indones. J. Nutr. 4, 89–95 (2016).

10. Kurniawan, N. D., Setiani, B. E. & Dwoloka, B. K. Fad Kedelai Lemak, Kadar Air, Kadar Protein, dan Antioksidan Tempe Edamame (Glycine max (L) Merrill) Dengan Jenis Pengemas Yang Berbeda. J. Teknol. Pangan 3, 355–358 (2019).

11. Maruthi, J. & Paramesh, R. Effect of integrated nutrient management on seed quality of vegetable soybean [Glycine max (L) Merrill] cv. Karune. Legum. Res. 39, 578–583 (2016).

12. Xu, Y., Cartier, A., Kibet, D., Jordan, K., Hakala, I., Davis, S., Sismour, E., Kering, M. & Rutto, L. Physical and nutritional properties of edamame seeds as influenced by stage of development. J. Food Meas. Character. 10, 193–200 (2016).

13. Zeipina, S., Alisma, I. & Leps, L. Insight in edamame yield and quality parameters: A review. In Research for Rural Development vol. 2 40–44 (2017).

14. Multari, S., Stewart, D. & Russell, W. R. Potential of Fava Bean as Future Protein Supply to Partially Replace Meat Intake in the Human Diet. Compr. Rev. Food Sci. Food Saf. 14, 511–522 (2015).

15. Radiati, A. & Sumarto. Analisis Sifat Fisik, Sifat Organoleptik, dan Kandungan Gizi pada Produk Tempe dari Baccharis Sambungmatai. J. Apl. Teknol. Pangan 5, 16–22 (2016).

16. Ali, N. M., Yeap, S. K., Yusof, H. M., Beh, B. K., Ho, W. Y., Koh, S. P., Abdullah, M. P., Altheen, N. B. & Long, K. Comparison of free amino acids, antioxidants, soluble phenolic acids, cytotoxicity and immunomodulation of fermented mung
17. Astawan, M., Mardhiyyah, Y. S. & Wijaya, C. H. Potential of Bioactive Components in Tempe for the Treatment of Obesity. *J. Gizi dan Pangan* **13**, 79–86 (2018).

18. Kustayawati, M. E., Nawansih, O. & Nurdjanah, S. Profile of aroma compounds and acceptability of modified tempeh. *Int. Food Res. J.* **24**, 734–740 (2017).

19. Santos, V. A. Q. Nascimento, C. G., Schmidt, C. A. P., Mantovani, D., Dekker, R. F. H. & Cunha, M. A. da. Solid-state fermentation of soybean okara: Isoflavones biotransformation, antioxidant activity and enhancement of nutritional quality. *Lwt* **92**, 509–515 (2018).

20. Pengkumrri, N., Suvarmaruthi, B. S., Sirilun, S., Peerajan, S., Kesiaka, P., Chaiayasut, K. & Chaiayasut, C. Extraction of β-glucan from Saccharomyces cerevisiae: Comparison of different extraction methods and in Vivo assessment of immunomodulatory effect in mice. *Food Sci. Technol.* **37**, 124–130 (2017).

21. Henrion, M., Francey, C., Lè, K. A. & Lamothe, L. Cereal B-glucans: The impact of processing and how it affects physiological responses. *Nutrients* **11**, 1–14 (2019).

22. Rizal, S., Kustayawati, M. E., Murhadi & Hasanudin, U. The Growth of Yeast and Fungi, the formation of β-Glucan, and the Antibacterial Activities during Soybean Fermentation in Producing Tempeh. *Int. J. Food Sci.* 1–8 (2021) doi:10.1155/2021/6676042.

23. Nurkistin, D., Tamtomo, D. G. & Wibowoivini, B. International Nursing and Health Sciences Symposium. In Proximate and isoflavones content in edamame tempeh flour and modified edamame tempeh flour 14–21 (2021).

24. WHO. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization. (2000).

25. Salsabila, D. M., Maryusman, T. & Fatmawati, I. Pengaruh Sinbitok Kefir Tepung Pisang Batu (Musa balbisiana) terhadap Kadar Glukosa Darah Tiktus Sindrom Metabolik. *J. Bioteknol. Biosains Indones.* **7**, 18–27 (2020).

26. Parameshwar, P., Naik, G. N., Kumar, N. S. & Vidyasagar, M. Pharmacokinetic Profile of Wheat Bran on Hyperlipidemic Wistar Strain Rats. *Int J Biopharm.* **3**, 78–81 (2012).

27. Jafar, H., Kenta, Y. S. & Nurhaeni. Uji efek anti hipergkolesterolemia ekstrak etanol daun boroco merah terhadap tikus putih jantan hiperkolesterolemia. *Farmakol. J. Farm.* **XVI**, 26–34 (2019).

28. Nugraheni, K. & Bintari, S. H. Aktivitas antidiisipleidemia tepung tempe dan susu kedelai pada profil lipid tikus diabetes yang didukuki streptozotocin. *J. Gizi dan Diet. Indones.* **4**, 147–153 (2016).

29. Nishimura, M., Ohkawara, T., Sato, Y., Satoh, H., Takahashi, Y., Hajika, M. & Nishihira, J. Improvement of Triglyceride Levels through the Intake of Enriched-β-Conglycinin Soybean (Nanahomare) Revealed in a Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients* **8**, 1–14 (2016).

30. Lammi, C., Zanon, C. & Arnoldi, A. IAVPGVEA, IAVPTGV, and LPYP, three peptides from soy glucin, modulate cholesterol metabolism in HepG2 cells through the activation of the LDLR-SREBP2 pathway. *J. Funct. Foods* **14**, 469–478 (2015).

31. Caponio, G. R., Wang, D. Q. H., Di Ciaula, A., De Angelis, M. & Portincasa, P. Regulation of cholesterol metabolism by bioactive components of soy proteins: Novel translational evidence. *Int. J. Mol. Sci.* **22**, 1–18 (2021).

32. Khoury, D. El & Anderson, G. H. Recent advances in dietary proteins and lipid metabolism. *Curr Opin Lipidol* **243**, 207–213 (2013).

33. Food and Drug Administration (FDA). *Food labeling health claims; soy protein and coronary heart disease. Fed Regist* vol. 64 (2017).

34. Fairuz, A. & Nisa, K. Pengaruh Serat Pangan Terhadap Kadar Kolesterol Penderita Overweight. *J. Major*. **4**, 121–126 (2015).

35. Sima, P., Vannucci, L. & Vetvicka, V. β-gluccans and cholesterol (Review). *Int. J. Mol. Med.* **41**, 1799–1808 (2018).

36. Huang, Y. C., Wu, B. H., Chu, Y. L., Chang, W. C. & Wu, M. C. Effects of tempeh fermentation with lactobacillus plantarum and rhizopus oligosporus on streptozotocin-induced type II diabetes mellitus in rats. *Nutrients* **10**, 1–15 (2018).

37. Flórez-Méndez, J. & González, L. Role of the consumption of fusoidans and beta-gluccans on human health: An update of the literature. *Rev. Chil. Nutr.* **46**, 768–775 (2019).

38. Guillarducci, J. D. S., Marcelino, B. A. R., Konig, I. F. M., Orlando, T. M., Varaschin, M. S. & Pereira, L. J. Therapeutic effects of different doses of prebiotic (isolated from Saccharomyces cerevisiae) in comparison to n-3 supplement on glycemic control, lipid profiles and immunological response in diabetic rats. *Diabetol. Metab. Syndr.* **12**, 1–12 (2020).

39. Ramdath, D. D., Padhi, E. M. T., Sarfaraz, S., Renwick, S. & Duncan, A. M. Beyond the cholesterol-lowering effect of soy protein: A review of the effects of dietary soy and its constituents on risk factors for cardiovascular disease. *Nutrients* **9**(2017).

40. Sagith, D. V., Ilmiawati, C. & Katar, Y. Pengaruh Pemberian Ekstrak Biji Melinjo (Gnetum gnemon) Terhadap Kadar Kolesterol LDL Pada Tikus Galur Wistar (Rattus norvegicus) Model Hiperkolesterolemia. *J. Kesehat. Andalas* **213**, 486–491 (2013).

41. Uchendu, I. K., Onwukwe, O. S., Agu, C. E., Orji, O. C., Chekwube, B. E. & Nwosu, T. F. Hypolipidaemic and renoprotective effects of Glycinum max (Soy bean) against lipid profile and renal biochemical alterations in hypercholesterolemic rat. *Int. J. Biomed. Res.* **7**, 822–828 (2016).
42. Widiyawati, A. & Susindra, Y. Utilization of edamame soybean (Glycine max (L) Merril) as modified of enteral formula high calories. in IOP Conference Series: Earth and Environmental Science vol. 207 1–7 (2018).

43. Handayani, W. & Rudijanto, A. Mechanism of Polyunsaturated Fatty Acids in Soy Milk Against Insulin Resistance Improvement. J. Appl. Environ. Biol. Sci. 7, 185–190 (2017).

44. Kusmiati & Dhewantara, F. X. R. Cholesterol-lowering effect of beta glucan extracted from saccharomyces cerevisiae in rats. in Scientia Pharmaceutica vol. 84 153–165 (2016).

45. Grundy, M. M. L., Fardet, A., Tosh, S. M., Rich, G. T. & Wilde, P. J. Processing of oat: the impact on oat’s cholesterol lowering effect. Food Funct. 9, 1328–1343 (2018).

46. Sokol-Wysoczańska, E., Wysoczański, T., Wagner, J., Czyz, K., Bodkowski, R., Lonczyński, S. & Patkowska-Sokola, B. Polyunsaturated fatty acids and their potential therapeutic role in cardiovascular system disorders—a review. Nutrients 10, 1–21 (2018).

47. Astawan, M., Wresdiyati, T. & Saragih, A. M. Evaluasi Mutu Protein Tepung Tempe dan Tepung Kedelai Rebus Pada Tikus Percobaan Evaluation of Protein Nutritional Quality of Tempe and Boiled Soybean Flours by Rats. J. Mutu Pangan Indonesia. J. Food Qual. 2, 11–17 (2015).

48. Astawan, M., Wresdiyati, T. & Sirait, J. Pengaruh Konsumsi Tempe Kedelai Grobongan terhadap profil Serum, Hematologi, dan Antioksidan Tikus. J. Teknol. dan Ind. Pangan 26, 155–162 (2015).

49. Nachvak, S. M., Moradi, S., Anjom-Shoae, J., Rahmani, J., Nisiri, M., Maleki, V. & Sadeghi, O. Soy, Soy Isoflavones, and Protein Intake in Relation to Mortality from All Causes, Cancers, and Cardiovascular Diseases: A Systematic Review and Dose–Response Meta-Analysis of Prospective Cohort Studies. J. Acad. Nutr. Diet. 119, 1–35 (2019).

50. Herwana, E. & Graciela, A. High dietary daidzein intake lowers cholesterol levels among post-menopausal women. Universa Medica 39, 47–54 (2020).

51. Froyen, E. & Burns-Whitmore, B. nutrients The Effects of Linoleic Acid Consumption on Lipid Risk Markers for Cardiovascular Disease in Healthy Individuals: A Review of Human Intervention Trials. Nutrients 12, 1–19 (2020).

52. Inoue, N., Fujiwara, Y., Funayama, A., Ogawa, N., Tachibana, N., Kohno, M. & Ikeda, I. Soybean β-conglycinin improves carbohydrate and lipid metabolism in Wistar Rats. Biosa. Biotecnol. Biochem. 79, 1528–1534 (2015).

53. Afifah, D. N., Nabila, N., Supradam G. T., Pratiwi, S. N., Nuryanto. & Sulchan, M. The Effects of Tempeh Gembus, an Indonesian Fermented Food, on Lipid Profiles in Women with Hyperlipidemia. Curr. Nutr. Food Sci. 16, 56–64 (2020).

54. Barańska, A., Blaszczuk, A., Polz-Oracz, M., Kanadyz, W., Malm, M., Janiszewska, M. & Jedrych, M. Effects of Soy Isoflavones on Glycemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 13, 2–19 (2021).